-
Most Popular
Healthcare Stocks
Healthcare encompasses a wide range of organized services to prevent, treat, and diagnose medical needs and mental illnesses. The $336 billion market is expected to grow at a compound annual growth rate of 8% until 2030, demonstrating the necessity of adequate healthcare. Healthcare companies, ranging from retailer CVS to insurance giant UnitedHealth, provide these services to a massive customer base.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
7 Dependable Dividend Stocks for Long-Term Income
Explore the best dividend stocks for long-term income excelling in the healthcare, retail, tobacco and home improvement markets.
3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct
These are the pharmaceutical stocks to buy as they represent undervalued companies with a deep clinical pipeline that will support growth.
Other industries you might be interested in
Recent Healthcare Stocks Articles
Pair-Trading Cannabis Stocks: Go Long THC and Short CBD
Cannabis stocks have taken a huge hit in 2019 and will likely remain volatile while the industry goes through its growing pains. Long-term cannabis bulls can consider mitigating their portfolio risk by going long top legal cannabis producers and short CBD-focused stocks.
The Clock Is Ticking for Aurora Cannabis After a Tough Year
Aurora Cannabis hopes that CBD oil and converting debt to equity can save it from the scrap heap.
It Doesn’t Look as If 2020 Will Be Any Better for Hexo Stock
Cash burn will result in equity dilution. Slower growth likely in medicinal and recreational cannabis due to regulatory headwinds.
Why Longer-Term Investors Should Buy Amarin Stock on Weakness
Short sellers have targeted AMRN and the Amarin stock price is quite undervalued, making the shares quite attractive for long-term investors.
A Close Look Shows New Age Beverages Stock Remains a Sell
NBEV stock is intriguing as its revenue is growing and it has a CBD opportunity. But NBEV is failing to deliver on its promise.
Canopy Growth Is Halfway to a Full Blown Recovery
Investors who are looking for marijuana stocks should have CGC on their radar as it looks like the best of the bunch right now.
Aurora Cannabis Will Survive, But It’s Still a Poor Investment
Aurora Cannabis isn't going to go bankrupt soon, so don't worry about that. But those fears show just how far it has fallen.
Collect on the Pharmaceutical Boom With Eli Lilly
Eli Lilly and Company (NYSE:LLY) provided optimistic guidance for 2020 today, and it looks like the stock will head higher at the open this morning.
Canopy Growth Stock Rally Should Offer Many Trading Opportunities
There are profits in trading Canopy Growth stock as the sector finds its footing on Wall Street. CGC is in a rebound effort from earnings.
You Can’t Afford to Miss This Buying Opportunity
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.
Why There’s No Rush to Buy Tilray Stock Anytime Soon
TLRY stock is down big since the passage of the MORE Act, and that's a sign of more troubles to come for Tilray stock.
With a Cloudy Future and Shaky Financials, NBEV Stock Is a Falling Knife
At this point NBEV stock looks like a falling knife with very little upside potential.
Canopy Growth Stock Popped — What’s Going On?
Canopy Growth stock has enjoyed a rare week of good news. But investors should hold off on buying CGC stock for now.
Canopy Growth Needs You to Call the Cops
Canopy Growth hopes that infusing chocolate with THC will deliver high sales that legal bud hasn't under new CEO David Klein.
Can Cronos Stock Break Out of Its Downtrend?
Cronos stock is surviving thanks to its large cash balance. However, can CRON stock finally turn the corner and snap out of its funk?
Patience With Aurora Cannabis Will Pay Off in 2020
Presently depressed Canadian consumer cannabis demand trends could reverse in 2020. If they do, Aurora Cannabis could rebound in a big way.
Consider Aphria Stock as the Cannabisphere Burns
But does this make APHA stock a buy today? Perhaps. Analyst consensus projects positive earnings-per-share for Aphria stock in 2020 and 2021. Meanwhile, the above-mentioned peers will remain unprofitable. The bigger names dominate the headlines. But under-the-radar Aphria may be the best "pot stock" buy.
Why Investors Should Continue to Say No to Hexo Stock
At the end of the day, the cannabis industry will birth only 5 to 10 big winners, and HEXO stock likely won't be one of them.
